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ABSTRACT 
Imrnunotoxins are therapeutic agents that directly target toxins to specific cells and are 
generally comprised of an antibody or antibody fragment (Fab or scFv) linked to a toxic 
moiety. The assessment of a number of imrnunotoxins in recent Phase I and 11 clinical 
trials has been very promising, particularly for the treatment of haematological 
malignancies. Since the majority of these incorporate large, potent bacterial or plant 
toxins, their therapeutic potential is limited by dose-limiting non-specific toxicity, 
imrnunogenicity and the need to be endocytosed. An alternative approach is to 
incorporate cytolytic toxins such as melittin and pilosulin that are smaller, less toxic 
molecules that act at the cell membrane. Both melittin- and pilosulin-based 
imrnunotoxins (mel-IT and pil-IT) have been developed by our research group. These 
cytolytic imrnunotoxins, which incorporate a scFv moiety specific for the human kappa 
myeloma antigen (KMA) expressed on human kappa myeloma cells and the human 
lymphoblastoid cell line, HMy2, display specific cytotoxic activity at micromolar 
concentrations against the target cell line. In contrast, imrnunotoxins in clinical and late 
stage pre-clinical studies are active at picomolar concentrations and thus it was deemed 
necessary to enhance the specific activity of mel-IT and pil-IT to ensure they could be 
effective at relevant clinical doses. 
The pil-IT displayed greater cytotoxic potential as peptide studies indicated that 
pilosulin was four times more potent than melittin against white blood cells (WBCs) 
and additionally, the pil-IT was shown to be twice as toxic as the mel-IT on a molar 
basis. In order to identify the regions of pilosulin essential for cytolytic activity and 
thus develop a smaller imrnunotoxin, two recombinant constructs were generated that 
encoded truncated toxin domains; P1-22F (incorporating the N-terminal helix of 
pilosulin, amino acid residues 1 to 22) and P23-s~ (incorporating the C-terminal helix, 
residues 23 to 56). Unexpectedly, both recombinant constructs displayed reduced 
cytolytic activity compared to the parent construct (pil-IT/ Pt-s~), due to reduced 
specific binding of the imrnunotoxins to the target cells, presumably as a result of 
incorrect tertiary folding of the expressed proteins. In a further attempt to increase the 
specific activity of the pilosulin-based imrnunotoxin, two additional constructs were 
generated; P121F which had a longer linker arm between the full-length pilosulin peptide 
and the antigen-specific scFv moiety to enhance steric access of the toxin to the target 
cell membrane, and P A33K4tF which contained the C-terminal helical region of pilosulin 
in an enhanced helical conformation to aid membrane interaction and penetration. 
While preliminary studies indicated that both constructs had cytotoxicity comparable 
the parent, neither exhibited enhanced cytolytic activity. 
Contaminant proteins were observed to be eo-purifying with the immunotoxins raising a 
question as to whether these contaminants may have had the potential to affect the 
cytolytic activity of pil-IT. The most significant contaminant was identified as apoA-1, 
a 27-kDa hydrophobic serum protein that had previously been shown to inhibit the 
activity of cytolytic peptides and also to stabilise damaged membranes. As the FBS 
used to supplement the expression culture medium was identified as the source ofapoA-
1, the pil-IT immunotoxin was expressed in serum-free medium. The recombinant 
protein expressed under these conditions was extremely susceptible to proteolysis in the 
cell culture medium and attempts to block this proteolysis by supplementing the 
cultures with BSA or a2-macroglubulin were ineffective. However, supplementing the 
serum-free expression cultures with E-64, a specific cysteine protease inhibitor, blocked 
the majority of the proteolytic degradation of pil-IT and allowed affinity purification of 
a very pure immunotoxin preparation. 
Unexpectedly, pil-IT expressed in this manner displayed significant non-specific 
toxicity compared to previous immunotoxin batches. It is possible that the presence of 
E-64 in the culture supematant affected the tertiary fold of the immunotoxin so that it 
acted independently of the antigen binding specificity encoded by the scFv moiety, or 
that pil-IT in a very pure form is very toxic and non-specific (i.e. a true result of an 
'apoA-1 free'-immunotoxin preparation). Another issue requiring consideration was 
that the insect cell line used for expression of the non-specific toxic batches of 
immunotoxin in serum-free medium (High Five cells) was different to that used to 
express batches of specifically cytotoxic immunotoxin in serum-containing medium 
(Sf21 insect cells). 
To address this question, the pil-IT was expressed in High Five insect cells in the 
presence of FBS and then affinity purified with a Tween-20 wash step to dissociate the 
apoA-1 from the immunotoxin. While this produced a pure preparation, non-specific 
cytolytic activity was again observed, although to a lesser degree than that observed for 
the batches expressed with E-64 supplementation. Tween-20 was found to contribute to 
some of this non-specific activity but was not the sole factor, as pil-IT expressed in 
High Five cells in the presence of FBS and purified without Tween also exhibited non-
specific cytotoxicity. Thus it was likely to be a result of either (i) expressing the 
immunotoxin in High Five insect cells which, in contrast to Sf21 cells, may generate a 
tertiary fold in the immunotoxin that allows it to act non-specifically, or (ii) the absence 
(or low levels) of apoA-1, which when present in the immunotoxin preparation, may 
have inhibited its non-specific cytolytic activity and/or repaired toxin-induced cell 
membrane damage, with the strength of this effect varying for different cell membranes. 
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